Anastasios Konidaris
CFO
CFO
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Amneal Pharmaceuticals, Inc. (AMRX) | EVP & Chief Financial Officer | $600,750 | $3,293,494 |
| 2024 | Amneal Pharmaceuticals, Inc. (AMRX) | EVP & Chief Financial Officer | $580,731 | $2,852,333 |
| 2023 | Amneal Pharmaceuticals, Inc. (AMRX) | EVP & Chief Financial Officer | $563,327 | $1,891,266 |
| 2022 | Amneal Pharmaceuticals, Inc. (AMRX) | EVP & Chief Financial Officer | $550,000 | $2,733,186 |
| 2021 | Amneal Pharmaceuticals, Inc. (AMRX) | EVP & Chief Financial Officer | $550,000 | $2,663,996 |
| 2020 | Amneal Pharmaceuticals, Inc. (AMRX) | EVP & Chief Financial Officer | $427,308 | $2,508,499 |
Earnings-call appearances
-
Amneal Pharmaceuticals, Inc. Q4 FY2024 Earnings Call2025-02-28
Amneal Pharmaceuticals, Inc. (AMRX)
-
Amneal Pharmaceuticals, Inc. Q1 FY2024 Earnings Call2024-05-03
Amneal Pharmaceuticals, Inc. (AMRX)
-
Amneal Pharmaceuticals, Inc. Q3 FY2022 Earnings Call2022-11-04
Amneal Pharmaceuticals, Inc. (AMRX)
-
Amneal Pharmaceuticals, Inc. Q2 FY2022 Earnings Call2022-08-05
Amneal Pharmaceuticals, Inc. (AMRX)
-
Amneal Pharmaceuticals, Inc. Q1 FY2021 Earnings Call2021-05-07
Amneal Pharmaceuticals, Inc. (AMRX)
-
Amneal Pharmaceuticals, Inc. Q2 FY2020 Earnings Call2020-08-06
Amneal Pharmaceuticals, Inc. (AMRX)